Krsnaa Diagnostics Limited (KRSNAA) AI Stock Analysis

• Market Cap: ₹23.03B
• Dividend Yield: 0.38%
• Average Volume (3M): 12.28K
• Price to Earnings (P/E): 26.9
• Beta (1Y): 1.10
• Revenue Growth: 11.51%
• EPS Growth: 21.56%
• Country: IN
• Employees: 3,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 7.50
• Shares Outstanding: 32,438,670
• 10 Day Avg. Volume: 19,408
• 30 Day Avg. Volume: 12,281
• PEG Ratio: 0.98
• Price to Book (P/B): 2.95
• Price to Sales (P/S): 3.63
• P/FCF Ratio: -66.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: ₹753.00 ▲(2.44% Upside)

Krsnaa Diagnostics Limited shows strong financial performance with solid revenue growth and a robust balance sheet. However, technical analysis indicates potential bearish momentum, and the valuation suggests moderate pricing with a low dividend yield. The lack of earnings call data and corporate events limits additional insights.

Positive Factors

Strong Capital Structure

A high equity ratio and very low leverage provide durable financial flexibility. Low debt reduces refinancing and interest burden risk, enabling the company to bid on capital-intensive PPP projects, fund equipment refreshes and absorb reimbursement timing shocks without stressing liquidity.

Robust Revenue & Margins

Double-digit revenue growth paired with very high gross margins points to a scalable diagnostics model with efficient lab utilization. Durable margin strength supports reinvestment in network and technology, providing resilience to volume cycles and capacity to expand services over time.

Solid Cash Conversion

Operating cash flow exceeding net income shows earnings largely convert to cash, supporting working capital and recurring equipment maintenance. Strong cash conversion underpins operational sustainability and helps fund ongoing network operations despite periodic capex needs.

Negative Factors

Negative Free Cash Flow

Material negative free cash flow driven by capital expenditure can constrain the company’s ability to self-fund expansion and equipment upgrades. Persistent FCF deficits may require external financing, increasing funding costs and exposing the business to liquidity pressure during contract or demand slowdowns.

Concentration on PPP Contracts

Heavy reliance on public-private partnerships concentrates revenue exposure to tariffs, contract renewals and public payment cycles. Structural dependence creates risk of pricing pressure, slower collections and renegotiation outcomes that can materially affect volumes and margins long term.

Modest Return on Equity

An ROE below double digits suggests shareholder capital is producing moderate returns relative to growth and capital intensity. This may indicate underutilized assets or margin headroom; without efficiency or margin improvement, ROE may limit long-term shareholder value creation.

Krsnaa Diagnostics Limited Business Overview & Revenue Model

Company Description

Krsnaa Diagnostics Limited provides diagnostic services. The company offers a range of technology-enabled diagnostic services, such as radiology, pathology/clinical laboratory, and tele-radiology services to public and private hospitals, medical colleges, and community health centers. As of December 31, 2020, it operated 1,801 diagnostic centers in 13 states across India. The company was incorporated in 2010 and is based in Pune, India.

How the Company Makes Money

Krsnaa Diagnostics generates revenue primarily through its diagnostic services, including laboratory tests and imaging services. The company operates both a network of diagnostic centers and mobile diagnostic units, allowing it to reach a broad customer base. Key revenue streams include direct payments from patients for diagnostic tests, as well as contracts with hospitals and healthcare providers that refer patients for diagnostic services. Additionally, KRSNAA has established partnerships with government health initiatives and insurance companies, further enhancing its revenue opportunities by providing services through public health schemes and insurance reimbursements.

Krsnaa Diagnostics Limited Financial Statement Overview

Summary

Krsnaa Diagnostics Limited demonstrates strong financial performance with robust revenue growth and profitability. The balance sheet is solid with a strong equity position and low leverage, enhancing financial stability. However, challenges in free cash flow generation present a potential risk, despite stable operating cash flows.

Income Statement

Krsnaa Diagnostics Limited shows strong revenue growth with a notable increase of 15.74% from 2024 to 2025. The company maintains a substantial gross profit margin of 76.38% for 2025, reflecting efficient cost management. However, while the net profit margin improved to 10.82%, there is room for enhancement in profitability metrics such as EBIT and EBITDA margins, which stand at 14.19% and 26.51% respectively. Overall, the income statement indicates a solid performance with positive growth trends.

Balance Sheet

The balance sheet of Krsnaa Diagnostics Limited is quite robust, with a healthy equity ratio of 68.87%, indicating a strong equity position relative to total assets. The debt-to-equity ratio at 0.23 suggests low financial leverage, which is a positive sign for financial stability. Additionally, the return on equity (ROE) is 8.79%, showing decent returns for shareholders. The balance sheet reflects sound financial management with a strong equity base and controlled leverage.

Cash Flow

The cash flow statement reveals challenges in free cash flow generation, with a negative free cash flow of -393 million in 2025, albeit an improvement from the previous year. The operating cash flow to net income ratio of 1.13 is solid, indicating good cash conversion efficiency. However, the company has faced difficulties in managing capital expenditures, which impacts free cash flow. Overall, while operating cash flows are stable, the negative free cash flow presents a potential risk area to address.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.40B	7.17B	6.20B	4.87B	4.55B	3.96B
Gross Profit	4.63B	5.48B	2.05B	4.13B	3.95B	3.13B
EBITDA	2.17B	2.16B	1.61B	1.42B	1.46B	3.59B
Net Income	802.09M	776.08M	568.37M	621.11M	683.88M	1.85B
Balance Sheet
Total Assets	0.00	12.82B	11.72B	9.10B	8.76B	6.05B
Cash, Cash Equivalents and Short-Term Investments	684.36M	684.36M	535.45M	1.09B	2.42B	1.53B
Total Debt	0.00	2.04B	1.60B	324.81M	409.92M	2.32B
Total Liabilities	-8.83B	3.99B	3.62B	1.71B	2.07B	3.73B
Stockholders Equity	8.83B	8.83B	8.10B	7.39B	6.84B	2.32B
Cash Flow
Free Cash Flow	0.00	-393.00M	-1.70B	-650.59M	-37.95M	357.18M
Operating Cash Flow	0.00	873.27M	243.45M	763.01M	1.28B	1.03B
Investing Cash Flow	0.00	-996.09M	-1.29B	-1.09B	-2.41B	-611.39M
Financing Cash Flow	0.00	137.53M	841.87M	-331.45M	1.76B	308.40M

Krsnaa Diagnostics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 735.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KRSNAA, the sentiment is Negative. The current price of 735.1 is above the 20-day moving average (MA) of 720.44, below the 50-day MA of 739.44, and below the 200-day MA of 762.03, indicating a bearish trend. The MACD of -8.19 indicates Negative momentum. The RSI at 44.16 is Neutral, neither overbought nor oversold. The STOCH value of 51.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KRSNAA.

Krsnaa Diagnostics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	75 Outperform	₹98.30B	63.55	―	0.20%	16.71%	13.92%
HCG	67 Neutral	₹83.44B	233.95	―	―	17.58%	-38.20%
LALPATHLAB	66 Neutral	₹235.94B	44.07	―	0.89%	10.80%	32.79%
KRSNAA	62 Neutral	₹23.03B	26.94	―	0.38%	11.51%	21.56%
METROPOLIS	61 Neutral	₹97.21B	58.86	―	0.21%	15.41%	5.93%
MEDICAMEQ	57 Neutral	₹4.65B	42.51	―	0.26%	-9.16%	49.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Krsnaa Diagnostics Limited Corporate Events

Krsnaa Diagnostics Schedules One-on-One Investor Meet in Mumbai

Krsnaa Diagnostics Limited has informed the stock exchanges that its officials will meet investors and analysts from First Water Capital in Mumbai on January 8, 2026, for a one-on-one, in-person interaction starting at 11:30 a.m. IST. The company clarified that the discussions will be limited to publicly available information, with no unpublished price-sensitive information to be shared, and noted that the schedule may change due to exigencies on the part of either the investors or the company.

Krsnaa Diagnostics Schedules Investor Meeting for November 27

Krsnaa Diagnostics Limited has announced a scheduled meeting with investors and analysts on November 27, 2025, in Mumbai. The meeting, which will be a one-on-one interaction with Athena Investments, aims to discuss publicly available information without sharing any unpublished price-sensitive information, reflecting the company’s commitment to transparency and compliance with regulatory requirements.

Krsnaa Diagnostics Releases Unaudited Financial Results for September 2025

Krsnaa Diagnostics Limited announced the publication of its unaudited financial results for the quarter and half-year ending September 30, 2025, in prominent newspapers. This disclosure is part of the company’s compliance with SEBI regulations and reflects its commitment to transparency with stakeholders.

Krsnaa Diagnostics Achieves Record Profit, Eyes Future Growth with Rajasthan Expansion

Krsnaa Diagnostics Limited reported its highest-ever quarterly profit, with a 12% year-on-year revenue growth in H1 FY26, driven by expanding patient volumes and confidence in its diagnostic network. The company’s EBITDA increased by 18% year-on-year, reflecting strong operating leverage and disciplined execution. The Rajasthan rollout is expected to unlock future growth potential, further strengthening Krsnaa’s market position. The company’s focus on profitable and sustainable growth is underscored by a 19% rise in net profit, and its strategic partnerships with government entities ensure quality receivables and credibility.